Who
Dawn Svoronos
Director
Company insider
Files Form 4 as: Director, Xenon Pharmaceuticals; Director, Adverum Biotechnologies; Director, Acelyrin; Director, Global Blood Therapeutics; Director, PTC Therapeutics; Director, Endocyte; Director, Medivation.
In numbers
- Trades disclosed
- 123
- Buys
- 5
- Sells
- 12
- Bought
- $974K
- Sold
- $2.3M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 22 Apr 2013
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $42K5,144 at $8.15 | filing |
| 1 Sep 2026filed 3 Sep 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,144 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,144 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $42K5,144 at $8.15 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,507 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,593 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $76K1,416 at $53.41 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,645 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,645 | filing |
| 1 Jun 2026filed 3 Jun 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $76K1,416 at $53.41 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,520 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,450 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Has Average Target Price of $70.27XENE · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Dawn Svoronos; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.